

The removal of airborne SARS-CoV-2 and other microbial bioaerosols by air filtration on COVID-19 surge units

Andrew Conway-Morris PhD^{±1,2}, Katherine Sharrocks DPhil^{±3}, Rachel Bousfield BMBS^{±3,4}, Leanne Kermack MSc^{±5}, Mailis Maes MPhil⁵, Ellen Higginson PhD⁵, Sally Forrest BSc⁵, Joana Pereira-Dias MSc⁵, Claire Cormie⁵, Tim Old MA³, Sophie Brooks MSc³, Islam Hamed FRCA¹, Alicia Koenig MBChB¹, Andrew Turner⁶, Paul White PhD^{6,7}, R. Andres Floto FRCP^{8,9}, Gordon Dougan D.Sc⁵, Effrossyni Gkrania-Klotsas PhD^{¥3}, Theodore Gouliouris PhD^{¥3,4}, Stephen Baker PhD⁵, and Vilas Navapurkar FFICM^{1*}

1 The John Farman ICU, Cambridge University Hospitals NHS Foundation Trust, Hills Rd, Cambridge CB2 0QQ, UK

2 University Division of Anaesthesia, Department of Medicine, University of Cambridge School of Clinical Medicine, Cambridge Biomedical Campus, Cambridge, UK

3 Department of Infectious Diseases, Cambridge University Hospitals NHS Foundation Trust, Hills Rd, Cambridge CB2 0QQ, UK

4 Clinical Microbiology Laboratory, Cambridge University Hospitals NHS Foundation Trust, Hills Rd, Cambridge CB2 0QQ, UK

5 Cambridge Institute of Therapeutic Immunology and Infectious Disease, Department of Medicine, University of Cambridge School of Clinical Medicine, Cambridge Biomedical Campus, Cambridge, UK

6 Department of Clinical Engineering, Cambridge University Hospitals NHS Foundation Trust, Cambridge UK

7 Medical Technology Research Centre and School of Medicine, Anglia Ruskin University, Chelmsford, UK

8 Molecular Immunity Unit, University of Cambridge Department of Medicine, MRC-Laboratory of Molecular Biology, Cambridge, UK

9 Cambridge Centre for Lung Infection, Royal Papworth Hospital, Cambridge UK

[±]The following authors contributed equally to this work

[¥]The following authors contributed equally to this work

* Address for Correspondence

The John Farman ICU, Addenbrooke's Hospital, Hills Rd, Cambridge CB2 0QQ, UK

Vilas.navapurkar@addenbrookes.nhs.uk

Running head

Removal of airborne SARS-CoV-2

Word count: Summary 243 main text 2,318

Key words

SARS-CoV-2; COVID-19; hospital infection control; air filtration

Competing interests

Vilas Navapurkar is the founder, Director, and shareholder of Cambridge Infection Diagnostics Ltd. Andrew Conway-Morris, Paul White, Gordon Dougan and Stephen Baker are members of the Scientific Advisory Board of Cambridge Infection Diagnostics Ltd. Theodore Gouliouris has received a research grant from Shionogi. R Andres Floto has received research grants and/or consultancy payments from GSK, AZ, Chiesi, Shionogi, Insmad, Thirty Technology. Effrossyni Gkrania-Klotsas has received a National Institute of Health Research Greenshoots Award

Author contributions

ACM conceptualisation, methodology, data analysis, writing-original draft

KS investigation, supervision, writing-review and editing

RB investigation, supervision, writing-review and editing

LK investigation, data analysis, supervision, writing-review and editing

MM investigation, writing-review and editing

EH investigation, data analysis, writing-review and editing

SF investigation, writing-review and editing

JD investigation, writing-review and editing

TO investigation, writing-review and editing

SBr investigation, writing-review and editing

IH investigation, writing-review and editing

AK investigation, writing-review and editing

AT investigation, writing-review and editing

PW conceptualisation, provision of resources, writing-review and editing

AF Provision of resources, writing-review and editing

GD conceptualisation, provision of resources, supervision, writing-review and editing

EG conceptualisation, supervision, investigation, writing-review and editing

TG conceptualisation, supervision, investigation, writing-review and editing

SB conceptualisation, provision of resources, supervision, data analysis, writing-original draft

VN conceptualisation, provision of resources, supervision, data analysis, writing-original draft

Funding

This work was supported by a Wellcome senior research fellowship to Stephen Baker

(215515/Z/19/Z). Andrew Conway Morris is supported by a Clinician Scientist Fellowship from the

Medical Research Council (MR/V006118/1). Mailis Maes and Sally Forrest are funded by the

National Institute for Health Research [Cambridge Biomedical Research Centre at the Cambridge

University Hospitals NHS Foundation Trust]. The views expressed are those of the authors and not

necessarily those of the NHS, the NIHR or the Department of Health and Social Care.

The funders had no role in the design and conduct of the study; collection, management, analysis, and

interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit

the manuscript for publication.

The study was registered as a service evaluation with Cambridge University Hospitals NHS Foundation Trust (Service Evaluation Number PRN 9798).

Summary

Background

The COVID-19 pandemic has overwhelmed the respiratory isolation capacity in hospitals; many wards lacking high-frequency air changes have been repurposed for managing patients infected with SARS-CoV-2 requiring either standard or intensive care. Hospital-acquired COVID-19 is a recognised problem amongst both patients and staff, with growing evidence for the relevance of airborne transmission. This study examined the effect of air filtration and ultra-violet (UV) light sterilisation on detectable airborne SARS-CoV-2 and other microbial bioaerosols.

Methods

We conducted a crossover study of portable air filtration and sterilisation devices in a repurposed ‘surge’ COVID ward and ‘surge’ ICU. National Institute for Occupational Safety and Health (NIOSH) cyclonic aerosol samplers and PCR assays were used to detect the presence of airborne SARS-CoV-2 and other microbial bioaerosol with and without air/UV filtration.

Results

Airborne SARS-CoV-2 was detected in the ward on all five days before activation of air/UV filtration, but on none of the five days when the air/UV filter was operational; SARS-CoV-2 was again detected on four out of five days when the filter was off. Airborne SARS-CoV-2 was infrequently detected in the ICU. Filtration significantly reduced the burden of other microbial bioaerosols in both the ward (48 pathogens detected before filtration, two after, $p=0.05$) and the ICU (45 pathogens detected before filtration, five after $p=0.05$).

Conclusions

These data demonstrate the feasibility of removing SARS-CoV-2 from the air of repurposed ‘surge’ wards and suggest that air filtration devices may help reduce the risk of hospital-acquired SARS-CoV-2.

Funding

Wellcome Trust, MRC, NIHR

1 **Introduction**

2 During the COVID-19 pandemic ‘general’ hospital wards in the UK were rapidly repurposed into
3 ‘surge’ wards and intensive care units (ICU), which lacked the capacity for high frequency air-
4 changes. Airborne dissemination is likely an important transmission route for SARS-CoV-2¹, with
5 SARS-CoV-2 RNA being detected in air samples from wards managing COVID-19 patients^{2,3}.
6 Despite the use of appropriate personal protective equipment (PPE) that filter medium and large size
7 droplets, there are multiple reports of patient-to-healthcare worker transmission of SARS-CoV-2^{4,5,6},
8 potentially through the inhalation of viral particles in small (< 5µM) aerosols⁷. Furthermore,
9 nosocomial acquisition of COVID-19 has continued to blight healthcare systems despite the
10 systematic introduction of patient and healthcare worker asymptomatic screening programmes⁸. There
11 is a need to improve the safety for healthcare workers and patients during the pandemic by decreasing
12 the potential for the airborne transmission of SARS-CoV-2⁷. Engineering solutions that improve
13 ventilation with provision of UV light sterilisation are considered a more effective intervention in the
14 hierarchy of controls against transmissible infections compared to enhanced respiratory protective
15 equipment^{9,10}. Portable air filtration systems, that combine high efficiency particulate filtration and
16 ultraviolet (UV) light sterilisation, may be a scalable solution for removing respirable SARS-CoV-2.
17 A recent review by the UK Scientific Advisory Group for Emergencies modelling group found
18 limited data regarding the effectiveness of such devices¹¹, which is consistent with findings from two
19 recent systematic reviews^{12,13}. Most of the testing of such systems has been physical device
20 validation using inorganic particles or removal of bacterial bioaerosols in controlled test environments
21^{12,13}. Here we present the first data providing evidence for the removal of SARS-CoV-2 and microbial
22 bioaerosols from the air using portable air filters with UV sterilisation on a COVID-19 ‘surge’ ward
23 during the ongoing pandemic.

24

25 **Methods**

26 *Setting*

27 The study was conducted in two repurposed COVID-19 units in Addenbrooke’s Hospital, Cambridge,
28 UK in January/February 2021 when the alpha variant (lineage B.1.1.7) comprised >80% of circulating

29 SARS-CoV-2⁸. One area was a ‘surge ward’ (ward) managing patients requiring simple oxygen
30 therapy or no respiratory support, the second was a ‘surge ICU’ (ICU) managing patients requiring
31 invasive and non-invasive respiratory support. The ward was a fully occupied four-bedded bay (Fig.
32 1A). The ICU was fully occupied five-bedded bay, with a super-capacity sixth occupied bed used in
33 week 2 (Fig. 1B).

34

35 In the ward we installed an AC1500 HEPA14/UV steriliser (Filtrex, Harlow, UK), whilst in the ICU
36 we installed a Medi 10 HEPA13/UV steriliser (Max Vac, Zurich, Switzerland) (supplemental
37 methods). The air filters were placed in fixed positions before the initiation of the three-week study
38 period (Fig. 1), switched on at the beginning of week two and run continuously from Sunday to
39 Sunday for 24 hours per day, providing approximately 5-10 room-volume filtrations per hour in each
40 location. As the devices do not meet medical device electrical safety standards (EN60601) they were
41 operated at a distance of ≥ 1.5 metres from any patient.

42 *Study design*

43 We performed a crossover evaluation, with the primary outcome being detection of SARS-CoV-2
44 RNA in the various size fractions of the air samples. Air sampling was conducted using National
45 Institute for Occupational Safety and Health (NIOSH) BC 251 two-stage cyclone aerosol samplers¹²
46 (Donated by B Lindsley, Centers for Disease Control, Atlanta), operated in accordance with previous
47 studies demonstrating capture of airborne viruses (supplemental methods)^{2,14-18}. Air samplers were
48 assembled daily with a sampler left in a sealed bag as a control. Samplers placed adjacent to the air
49 filter inlet and the other at approximately four meters and no closer than two meters to patients (Fig.
50 1). In ICU two distant samplers were used, one mounted at head height and one at bed height.

51

52 The samplers were operated on weekdays (0815hrs to 1415hrs) for three consecutive weeks. After
53 sampling, the samplers were disassembled using sterile technique and the filter papers were
54 transferred to 15 ml Falcon tubes. The samples were processed then stored at -80°C until analysis.

55 The samplers were washed with 80% ethanol and demineralised water.

56

57 *Pathogen detection*

58 Nucleic acids were extracted from each NIOSH sampler component (tubes containing large aerosols,
59 medium aerosols, and filter), as previously described¹⁹. Details of the RT-qPCR for SARS-CoV-2 and
60 multiplex qPCR assays for a range of respiratory and other bacterial, viral, and fungal pathogens are
61 in the supplemental section.

62

63 *Statistical analyses*

64 Differences in the number of pathogens detected when air filter was on and off were compared by
65 Mann-Whitney U-test. Statistical significance was inferred when p values were ≤ 0.05 . Graphs were
66 generated in R studio.

67

68 The study was registered as a service evaluation with Cambridge University Hospitals NHS
69 Foundation Trust (Service Evaluation Number PRN 9798).

70

71 **Results**

72 *Removal of SARS-CoV-2 by air filtration on surge ward*

73 For the duration of the study (18th January to 5th February) the beds in the ward and ICU were at
74 100% occupancy, with 15 patients admitted to the ward and 14 admitted to the ICU over the three-
75 week sampling period (7, 4, 4 in weeks 1-3 in the ward and 6, 5, 3 in the ICU, respectively). All
76 patients were symptomatic and tested positive for SARS-CoV-2 RNA from a respiratory sample
77 before admission. Patients in the ICU were managed with non-invasive mask ventilation, high flow
78 nasal oxygen or invasive ventilation via endotracheal tube or tracheostomy. Patients in the ward were
79 spontaneously ventilating with simple oxygen therapy or no respiratory support and no aerosol-
80 generating procedures performed.

81

82 In the ward, during the first week whilst the air filter was inactive, we were able to detect SARS-CoV-
83 2 on all five sampling days; RNA was detected in both the medium (1-4 μ M particle size) and the

84 large ($>4\mu\text{M}$ particle size) particulate fractions (Fig. 2A). SARS-CoV-2 RNA was not detected in the
85 small ($<1\mu\text{M}$) particulate filter. The air filter was switched on in week two and run continuously; we
86 were unable to detect SARS-CoV-2 RNA in any of the sampling fractions on any of the five testing
87 days. These initial observations provided evidence for the removal of SARS-CoV-2 via the air filter
88 system, albeit at high baseline C_T values. To confirm this observation, we completed the study by
89 repeating the sampling with an inactive air filter. As in week one, we were able to detect SARS-CoV-
90 2 RNA in the medium and the large particulate fractions on 3/5 days of sampling (a sample without
91 tube size indicated tested positive on day 5) (Fig. 2A). We did not detect SARS-CoV-2 RNA from the
92 control sampler.

93

94 *Removal of additional bioaerosols by air filtration on surge ward*

95 We subjected the extracted nucleic acid preparations to high-throughput qPCR using a Biomark HD
96 system to detect a range of viral, bacterial, and fungal targets. In the week one samples, we detected
97 nucleic acid from multiple viral, bacterial, and fungal pathogens on all sampling days (Fig. 2B). In
98 contrast, when the air filter was switched on, we detected yeast targets only on a single day, with a
99 significant reduction ($p=0.05$) in microbial bioaerosols when the air filter was operational (Fig. 2C).
100 Using this high-throughput approach, SARS-CoV-2 RNA was detected on 4/5 days tested in week 1
101 but was again absent in week 2. We were unable to generate multiplex data for week three due to
102 sample degradation after storage of sample following SARS-CoV-2 RNA amplification.

103

104 *Effectiveness of air filter on surge ICU*

105 In contrast to the ward, we found limited evidence of airborne SARS-CoV-2 in weeks one and three
106 (filter off) but detected SARS-CoV-2 RNA in a single sample in the medium ($1-4\mu\text{M}$ particle size)
107 particulates on week 2 (filter on) (Fig. 3A). This contrary result did not reflect a general lack of
108 bioaerosols in the ICU, which demonstrated a comparable quantity and array of pathogen associated
109 nucleic acids to that seen in the unfiltered ward air on week one (Fig. 3B). Again, the use of the air
110 filtration device significantly ($p=0.05$) reduced the microbial bioaerosols (Fig 3C); with only three

111 organism types detected on two of the sampling days (Fig 3B). SARS-CoV-2 RNA was only detected
112 once on the high-throughput qPCR assay, during week one.

113

114 **Discussion**

115 Our study represents the first report of successful removal of airborne SARS-CoV-2 in a hospital
116 environment using combined air filtration and UV sterilisation technology. Specifically, we provide
117 evidence for the circulation of SARS-CoV-2 in a ward within airborne droplets of $>1\mu\text{M}$. Droplets of
118 $1-4\mu\text{M}$ are likely a key vehicle for SARS-CoV-2 transmission, as they can remain airborne for a
119 prolonged period. They are also readily respirable and can deposit in the distal airways. Recent data
120 has shown that exertional respiratory activity, such as that seen in patients with COVID-19, increases
121 the release of $1-4\mu\text{M}$ respiratory aerosols, whilst conventionally defined ‘aerosol generating
122 procedures’ such as high flow nasal oxygen and non-invasive ventilation actively reduce aerosol
123 generation during exertion²⁰. These data are consistent with our observations, suggesting that
124 precautions to remove aerosolisation may be more important in conventional wards than in well
125 defined ‘aerosol risk areas’. We also found a low burden of SARS-CoV-2 in the air on the ICU. This
126 observation, combined with the higher level of aerosol protection worn by ICU staff, may explain
127 why staff in these areas appear to be at significantly lower risk of acquiring COVID than those
128 working on wards²¹.

129

130 The sampling and detection of airborne viruses poses several technological challenges, and although
131 several approaches have been developed, there remains no agreed standard for their use or
132 interpretation²². However, the detection of SARS-CoV-2 RNA by RT-qPCR (albeit at a high C_T
133 value), and the lack of detection during use of an air filtration/UV sterilisation system, adds to a
134 growing body of evidence implicating the airborne transmission of SARS-CoV-2¹. The detection of
135 SARS-CoV-2 RNA in the air of a ward managing patients with COVID-19 intimates that this is a key
136 mechanism by which healthcare professionals could become infected during patient care. The removal
137 of airborne viral particles and other pathogens may help reduce the likelihood of hospital-acquired

138 respiratory infections. This reduction may be by both decreasing the load of respirable particles and
139 by removal of larger droplets that can facilitate fomite-associated spread²². The clearance of
140 bioaerosol was not restricted to SARS-CoV-2. A range of bacteria, yeasts, and other respiratory
141 viruses with pathogenic potential were detected in the air of both rooms in the first week, with their
142 burden significantly reduced during air filtration. Although the impact of air filtration on nosocomial
143 infection is uncertain²³, the broad range of pathogens removed in this study suggests potential for
144 benefit beyond removal of SARS-CoV-2.

145

146 There are several potential explanations for the lower detection of SARS-CoV-2 in air of an ICU.
147 These include a later stage of disease during which viral replication is less pronounced²⁴, higher viral
148 loads in the lower rather than upper respiratory tract in critically ill patients²⁵ and use of respiratory
149 devices, which reduce aerosol generation²⁰. The reduction in microbial bioaerosols found in ICU
150 during the week of the air filtration system provides confidence that the device was similarly effective
151 to that used on the ward, despite the infrequent detection of SARS-CoV-2.

152

153 A recent systematic review of both static and portable air filtration, which also assessed relevant
154 building codes and guidelines¹², identified no robust studies of air filtration. Although multiple
155 building codes propose air filtration to protect vulnerable patients and to reduce risks of transmission
156 of airborne diseases, these have not been updated in light of COVID-19¹². Mousvai and colleagues
157 identified several studies demonstrating the capacity of air filtration to reduce inert, fungal, and
158 bacterial bioaerosols in experimental and clinical contexts. These findings are consistent with our
159 report, but previous data originate from fixed rather than portable air filtration devices. No reports of
160 SARS-CoV-2 removal were identified. A further recent review focussed solely on portable air
161 filters¹³, with studies demonstrating the removal of inert particles and deliberately aerosolised
162 bacteria, again no reports of SARS-CoV-2 removal were identified. The Centres for Disease Control
163 recommend the consideration of portable HEPA-based air filters; this recommendation applies only to
164 dental facilities where there is deemed to be a high risk of aerosol generation²⁶.

165

166 This study has limitations, being conducted rapidly in active wards during an ongoing pandemic. The
167 evaluation was conducted in two rooms and there are no data defining the optimal air changes
168 required to remove detectable pathogens with the specified devices. Given the large volume of air
169 within the room and the stability of viruses in the sampling fluid, it was predictable that the amount of
170 SARS-CoV-2 detected via qPCR would be minimal, as evidenced by high C_T values. Therefore, we
171 cannot categorically state that there was circulating infectious virus. RNA is sufficient to suggest the
172 virus was present and it has been shown that aerosolised virus can remain infectious for >3 hours^{27,28};
173 additionally, air sampling devices can artefactually reduce the apparent viability of sampled virus.
174 Negative results from the control sampler, and the striking but reversible effect of the air filtration
175 devices, suggest these are not false positive detections and we cannot exclude the risk of airborne
176 infection. Future studies should examine whether air filtration devices, such as those used here, have
177 an impact on healthcare professional and patient focussed outcomes, including measuring
178 infection/exposure as an endpoint, as well as assessing potential harm, such as noise, reduced ambient
179 humidity or impact on delivery of care.

180

181 In conclusion, we were able to detect airborne SARS-CoV-2 RNA in a repurposed COVID-19 ‘surge
182 ward’ and found that air filtration can remove SARS-CoV-2 RNA below the limit of qPCR detection.
183 SARS-CoV-2 was infrequently detected in the air of a ‘surge ICU’; however, the device retained its
184 ability to reduce microbial bioaerosols. Our data is highly indicative of aerosolised SARS-CoV-2
185 circulating in areas that are not classically considered ‘aerosol risk areas’. Furthermore, portable air
186 filtration devices can mitigate the reduced availability of airborne infection isolation facilities when
187 surges of COVID-19 patients overwhelm healthcare resources. The use of such systems may provide
188 additional safety for those that are of high exposure risk to respiratory pathogens such as SARS-CoV-
189 2.

190

191

192

193

194 **References**

- 195 1. Greenhalgh T, Jimenez JL, Prather KA, Tufekci Z, Fisman D, Schooley R. Ten scientific
196 reasons in support of airborne transmission of SARS-CoV-2. *Lancet*. 2021;397(10285):1603-
197 1605
198
- 199 2. Chia PY, Coleman KK, Tan YK, et al. Novel Coronavirus Outbreak Research Team. Detection
200 of air and surface contamination by SARS-CoV-2 in hospital rooms of infected patients. *Nat*
201 *Commun*. 2020;11(1):2800
202
- 203 3. Zhou J, Otter JA, Price JR, et al. Investigating SARS-CoV-2 surface and air contamination in
204 an acute healthcare setting during the peak of the COVID-19 pandemic in London. *Clin Infect*
205 *Dis*. 2020 Jul 8:ciaa905.
206
- 207 4. Nguyen LH, Drew DA, Graham MS, et al. Coronavirus Pandemic Epidemiology Consortium.
208 Risk of COVID-19 among front-line health-care workers and the general community: a
209 prospective cohort study. *Lancet Public Health*. 2020;5:e475-e483
210
- 211 5. Illingworth C, Hamilton W, Warne B, et al. Superspreaders drive the largest outbreaks of
212 hospital onset COVID-19 infection. *OSF Preprints*, 15 Feb.
213 2021. <https://doi.org/10.31219/osf.io/wmkn3>
214
- 215 6. Sims MD, Maine GN, Childers KL, et al; BLAST COVID-19 Study Group. COVID-19
216 seropositivity and asymptomatic rates in healthcare workers are associated with job function
217 and masking. *Clin Infect Dis*. 2020 Nov 5:ciaa1684. Epub ahead of print.
218
- 219 7. Fennelly KP. Particle sizes of infectious aerosols: implications for infection control. *Lancet*
220 *Respir Med*. 2020;8:914-924.
221
- 222 8. Meredith LW, Hamilton WL, Warne B, et al. Rapid implementation of SARS-CoV-2
223 sequencing to investigate cases of health-care associated COVID-19: a prospective genomic
224 surveillance study. *Lancet Infect Dis*. 2020 ;20:1263-1271
225
- 226 9. National Institute for Occupational Safety and Health National Institute for Occupational
227 Safety and Health. Hierarchy of controls. Available from
228 <https://www.cdc.gov/niosh/topics/hierarchy/default.html> (accessed 29/6/21)
229

230

231 10. Morawska L, Allen J, Bahnfleth W, et al. A paradigm shift to combat indoor respiratory
232 infection. *Science*. 2021;372:689-691

233

234 11. UK scientific advisory group for emergencies. Potential application of air cleaning devices and
235 personal decontamination to manage transmission of COVID-19, 4 November 2020
236 ([https://www.gov.uk/government/publications/emg-potential-application-of-air-cleaning-](https://www.gov.uk/government/publications/emg-potential-application-of-air-cleaning-devices-and-personal-decontamination-to-manage-transmission-of-covid-19-4-november-2020)
237 [devices-and-personal-decontamination-to-manage-transmission-of-covid-19-4-november-](https://www.gov.uk/government/publications/emg-potential-application-of-air-cleaning-devices-and-personal-decontamination-to-manage-transmission-of-covid-19-4-november-2020)
238 [2020](https://www.gov.uk/government/publications/emg-potential-application-of-air-cleaning-devices-and-personal-decontamination-to-manage-transmission-of-covid-19-4-november-2020))

239 12. Mousavi ES, Kananizadeh N, Martinello RA, Sherman JD. COVID-19 Outbreak and Hospital
240 Air Quality: A Systematic Review of Evidence on Air Filtration and Recirculation. *Environ*
241 *Sci Technol*. 2021;55:4134-4147.

242

243 13. Liu DT, Phillips KM, Speth MM, Besser G, Mueller CA, Sedaghat AR. Portable HEPA
244 Purifiers to Eliminate Airborne SARS-CoV-2: A Systematic Review. *Otolaryngol Head Neck*
245 *Surg*. 2021:1945998211022636

246

247 14. Lindsley WG, Schmechel D, Chen BT. A two-stage cyclone using microcentrifuge tubes for
248 personal bioaerosol sampling. *J Environ Monit*. 2006 ;8:1136-42.

249

250 15. Killingley B, Greatorex J, Digard P, et al The environmental deposition of influenza virus
251 from patients infected with influenza A(H1N1)pdm09: Implications for infection prevention
252 and control. *J Infect Public Health*. 2016;9:278-88.

253

254 16. Coleman KK, Sigler W V. Airborne Influenza A Virus Exposure in an Elementary School. *Sci*
255 *Rep*. 2020 Feb 5;10:1859.

256

257 17. Blachere FM, Lindsley WG, Slaven JE, et al. Bioaerosol sampling for the detection of
258 aerosolized influenza virus. *Influenza Other Respir Viruses*. 2007;1:113-20

259

260 18. Blachere FM, Lindsley WG, Pearce TA, et al. Measurement of airborne influenza virus in a
261 hospital emergency department. *Clin Infect Dis*. 2009;48:438-40.

262

263 19. Sridhar S, Forrest S, Kean I, et al. A blueprint for the implementation of a validated approach
264 for the detection of SARS-Cov2 in clinical samples in academic facilities. *Wellcome Open*
265 *Res*. 2020;5:110

266

- 267 20. Wilson NM, Marks GB, Eckhardt A, et al. The effect of respiratory activity, non-invasive
268 respiratory support and facemasks on aerosol generation and its relevance to COVID-19.
269 *Anaesthesia*. 2021 Mar 30. doi: 10.1111/anae.15475. Epub ahead of print.
270
- 271 21. Shields A, Faustini SE, Perez-Toledo M, et al SARS-CoV-2 seroprevalence and
272 asymptomatic viral carriage in healthcare workers: a cross-sectional study.
273 *Thorax* 2020;75:1089-1094
274
- 275 22. Stockwell RE, Ballard EL, O'Rourke P, Knibbs LD, Morawska L, Bell SC. Indoor hospital air
276 and the impact of ventilation on bioaerosols: a systematic review. *J Hosp Infect*.
277 2019;103:175-184.
278
- 279 23. Eckmanns T., Ruden H., Gastmeier P. The influence of high-efficiency particulate air filtration
280 on mortality and fungal infection among highly immunocompromised patients: a systematic
281 review. *J Infect Dis*. 2006;193:1408–1418
282
- 283 24. Wölfel R, Corman VM, Guggemos W, et al. Virological assessment of hospitalized patients
284 with COVID-2019. *Nature*. 2020;581:465-469
285
- 286 25. Hamed I, Shaban N, Nassar M, et al. Paired Nasopharyngeal and Deep Lung Testing for
287 Severe Acute Respiratory Syndrome Coronavirus-2 Reveals a Viral Gradient in Critically Ill
288 Patients: A Multicenter Study. *Chest*. 2021;159:1387-1390.
289
- 290 26. Centers for Disease Control and Prevention [Internet]. Atlanta: The Centers. Interim Infection
291 Prevention and Control Guidance for Dental Settings During the COVID-19 Response.
292 Available from: <https://www.cdc.gov/coronavirus/2019-ncov/hcp/dental-settings.html>.
293
- 294 27. Fears AC, Klimstra WB, Duprex P, et al. Persistence of Severe Acute Respiratory Syndrome
295 Coronavirus 2 in Aerosol Suspensions. *Emerg Infect Dis*. 2020 Sep;26(9):2168–71.
296
- 297 28. N van Doremalen N, Bushmaker T, Morris DH, et al. Aerosol and Surface Stability of SARS-
298 CoV-2 as Compared with SARS-CoV-1. *N Engl J Med*. 2020;382(16):1564-1567.
299
- 300
- 301
- 302

303

304 **Figure legends**

305

306 **Figure 1.** Location of the air filters and room layout.

307 A) Layout of the room on the ‘surge’ ward with four beds. B) Layout on the ‘surge’ ICU with six beds
308 including the addition of a further bed to increase occupancy (labelled with red box). Locations of the
309 NIOSH air samplers indicated by *. The air filters were installed in the marked locations and set to
310 operate at 1000 m³/hour. The room’s volumes are approximately 107 m³ and 195m³ respectively.
311 Fresh air was not supplied or extracted in these areas.

312

313 **Figure 2.** Bioaerosol detection in specific air sampler fractions over the three-week testing period on
314 the ‘surge’ ward.

315 A) C_T values for SARS-CoV-2 qPCR on air sample fractions collected daily from the ward. Colours
316 indicate the specific component of the sampler where SARS-CoV-2 was detected. Components
317 collected aerosols dependent on size fractions; large >4 μm , medium 1-4 μm , small <1 μm . B) Daily
318 detection of fungal, bacterial and viral bioaerosols detected by high-throughput qPCR collected during
319 weeks one (filter off) and two (filter on). The differences in C_T values between the regular qPCR (A)
320 and high-throughput qPCR (B) are a function of the microfluidics technology, and do not reflect
321 higher bioaerosol burdens. C) Stacked bar chart showing collated total number of bioaerosol
322 detections during weeks one (filter off) and two (filter on). * $p=0.05$ by Mann-Whitney U test.

323

324 **Figure 3.** Bioaerosol detection in specific air sampler fractions over the three-week testing period on
325 the ‘surge’ ICU.

326 A) C_T value for the single qPCR SARS-CoV-2 detection on day 9 (week 2) in the medium (1-4 μm
327 particle size) fraction. B) Daily detection of fungal, bacterial and viral bioaerosol detected by high-
328 throughput qPCR collected during weeks one (filter off) and two (filter on). The differences in C_T
329 values between the regular qPCR (A) and high-throughput qPCR (B) are a function of the

330 microfluidics technology, and do not reflect higher bioaerosol burdens. C) Stacked bar chart showing

331 collated total number of bioaerosol detections during weeks one (filter off) and two (filter on).

332 * $p=0.05$ by Mann-Whitney U test.

333

334

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).




Figure 1. Location of the air filters and room layout.

A) Layout of the room on the 'surge' ward with four beds. B) Layout on the 'surge' ICU with six beds including the addition of the additional bed to increase occupancy (labelled with red box). Locations of the NIOSH air samplers indicated by *. The air filters were installed in the marked locations and set to operate at 1000 m³/hour. The rooms volumes are approximately 107 m³ and 195m³ respectively. Fresh air was not supplied or extracted in these areas.

A

medRxiv preprint doi: <https://doi.org/10.1101/2021.09.16.21263684>; this version posted September 22, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).




**B****C**

Figure 2. Bioaerosol detection in specific air sampler fractions over the three-week testing period on the ‘surge’ ward.

A) C_T values for SARS-CoV-2 qPCR on air sample fractions collected daily from the ward. Colours indicate the specific component of the sampler where SARS-CoV-2 was detected. Components collected aerosols dependent on size fractions; large $>4 \mu\text{m}$, medium $1-4 \mu\text{m}$, small $<1 \mu\text{m}$. B) Daily detection of fungal, bacterial and viral bioaerosols detected by high-throughput qPCR collected during weeks one (filter off) and two (filter on). The differences in C_T values between the regular qPCR (A) and high-throughput qPCR (B) are a function of the microfluidics technology, and do not reflect higher bioaerosol burdens. C) Stacked bar chart showing collated total number of bioaerosol detections during weeks one (filter off) and two (filter on). $*p=0.05$ by Mann-Whitney U test.




Figure 3. Bioaerosol detection in specific air sampler fractions over the three-week testing period on the ‘surge’ ICU.

A) C_T value for the single qPCR SARS-CoV-2 detection on day 9 (week 2) in the medium (1-4 μm particle size) fraction. B) Daily detection of fungal, bacterial and viral bioaerosol detected by high-throughput qPCR collected during weeks one (filter off) and two (filter on). The differences in C_T values between the regular qPCR (A) and high-throughput qPCR (B) are a function of the microfluidics technology, and do not reflect higher bioaerosol burdens. C) Stacked bar chart showing collated total number of bioaerosol detections during weeks one (filter off) and two (filter on). * $p=0.05$ by Mann-Whitney U test.